Guardant Health (GH) PT Raised to $65 at Mizuho

Mizuho analyst Anthony Petrone raised the price target on Guardant Health (NASDAQ: GH) to $65.00 (from $60.00) while maintaining a Outperform rating.

The analyst commented: "We ran a Quick Poll of primary care physicians (PCPs) to gather early insights on GH's Shield cancer detection test, which recently received breakthrough device designation from the FDA. Based on formal acknowledgment from the FDA and our survey's results, we are raising our volume estimates for Shield in 4Q25, 2026, and beyond. Physician utilization was bullish, and respondents see ~60-70% ASP premium for a Multicancer test versus CRC-Only. We also raise our PT to $65 on our incrementally bullish Shield outlook."

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• MYR Group (MYRG) PT Lowered to $422 at Goldman Sachs
• Madison Square Garden Entertainment (MSGE) PT Raised to $103 at Guggenheim